Author: Editor

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85% of newly diagnosed glioblastoma patients are alive 12 months following treatment. Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf

Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.

Elise De, MD of Massachussetts General Hospital @MassGeneralNews discusses the robotic assisted urethral diverticulectomy.

Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses phase 2 Study of pembro plus platinum doublet chemotherapy and radiotherapy as first-line therapy for locally advanced NSCLC presented at this year’s virtual ASCO.

Salma Jabbour, MD @SalmaJabbour1 of Rutgers Cancer Institute of New Jersey @RutgersCancer discusses how patients tolerated this therapy? – Phase 2 Study of Pembro plus Platinum Doublet Chemotherapy and Radiotherapy as First-Line Therapy for Locally Advanced NSCLC.

Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL: Why are targeted therapies important in treating sALCL?

Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL: How ADCETRIS may impact the existing sALCL treatment landscape?

Eva Domingo-Domenech, MD of Institut Català d’Oncologia – Hospitalet discusses ADCETRIS for Treatment of Adult Patients with Previously Untreated sALCL: What study supported the approval of ADCETRIS for the treatment of adult patients with previously untreated sALCL?

Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.

Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.

John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)

John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)

John Kuruvilla, MD of Cleveland Clinic @ClevelandClinic discusses KEYNOTE-204: a randomized, open-label, phase III study of pembrolizumab vs. brentuximab vedotin in relapsed or refractory classic hodgkin lymphoma (R/R cHL)

Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural patients with breast cancer.

Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural patients with breast cancer.

Suneel Kamath, MD @SKamath_MD of Cleveland Clinic @ClevelandClinic discusses the effect of shorter time to treatment on survival in rural patients with breast cancer.

Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC) at this year’s virtual ASCO 2020.

Moshe Ornstein, MD @MosheOrnsteinMD of Cleveland Clinic @ClevelandClinic discusses a phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC) at this year’s virtual ASCO 2020.

Philadelphia, PA (May 28, 2020) – Oncoceutics, Inc. announced that it and its collaborators will present several abstracts at the virtual 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) from Friday, May 29th to Tuesday, June 2nd that highlight the clinical safety and efficacy of ONC201 across a number of clinical trials, age groups and tumor types, including H3 K27M-mutant diffuse midline glioma. Additionally, a dedicated abstract will present the rationale and design of the first-in-human clinical trial for ONC206, the company’s second molecule of its portfolio of imipridones to enter clinical development.“The data presented at ASCO…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Katharine Ullman, PhD of Huntsman Cancer Institute at the University of Utah @huntsmancancer and Adam Frost, MD, PhD of UC San Francisco @UCSFMedicine discusses the new insights that links cell division to cancer. ___________ To replace aging and worn cells, the body primarily uses a process called mitosis, in which one cell divides into two. When a cell is ready to divide, it duplicates its DNA so a complete copy is available for each of the daughter cells. In this process, the DNA pieces, or chromosomes, must be precisely apportioned into the daughter cells. If one cell has an incomplete…

Fumito Ito, MD, PhD of Roswell Park @RoswellPark discusses CX3CR1–CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. Read here: https://insight.jci.org/articles/view/133920?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research

Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities. … A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse. “We used CRISPR technology to carry out a genome-wide screen in leukemia cells to block thousands of genes at once. This is an extremely powerful tool that allowed us to identify a multitude of genes that fuel leukemia growth and…

Tannishtha Reya, PhD of UCSD @UCSDHealth discusses using genome-wide CRISPR technology to find leukemia’s vulnerabilities. _____________ A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse. “We used CRISPR technology to carry out a genome-wide screen in leukemia cells to block thousands of genes at once. This is an extremely powerful tool that allowed us to identify a multitude of genes that fuel leukemia growth and…

Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Read here: https://jitc.bmj.com/content/8/1/e000673

Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.

Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.

Jonathan Trent, MD, PhD @JTrentMDPhD of Sylvester Comprehensive Cancer Center @SylvesterCancer discusses the phase I study of the mutant IDH1 inhibitor ivosidenib and safety activity in patients with chondrosarcoma.

Philadelphia, PA (May 19, 2020) – Oncoceutics, Inc. announced that the latest research findings with ONC201 and its novel class of imipridones will be presented at the 2020 annual meeting of the American Association of Cancer Research (AACR) on June 22-24, 2020. The research presented at AACR highlights the antitumor and cancer prevention activity of ONC201 in tumor types with dysregulation of its two binding targets DRD2 and ClpP: H3 K27M-mutant diffuse midline glioma, endometrial cancer, medullary thyroid cancer, small cell lung cancer, and colon cancer. The presentations further highlight novel ONC201 biomarkers that help to further inform the clinical efficacy…

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer. ______________ Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year. “Urothelial cancer refers to a cancer…

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer. ______________ Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year. “Urothelial cancer refers to a cancer…

Seth Lerner, MD of Baylor College of Medicine @bcmhouston discusses the innovative approach option for treating upper tract urothelial cancer. ______________ Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year. “Urothelial cancer refers to a cancer…

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma. Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma. Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html  

Elliot Norry, MD of Adaptimmune Therapeutics discusses the SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS). Adaptimmune’s ADP-A2M4 was granted ODD by the FDA late last year for soft tissue sarcomas and Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of synovial sarcoma. Read here: https://www.globenewswire.com/news-release/2020/04/28/2023245/0/en/Positive-Opinion-for-Orphan-Drug-Designation-for-ADP-A2M4-in-the-European-Union-for-the-Treatment-of-Soft-Tissue-Sarcoma-from-EMA-Committee-of-Orphan-Medicinal-Products.html

Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with solid tumors.

Charis Eng, MD, PhD @charisengmdphd of Cleveland Clinic @clevelandclinic discusses the germline genomic profiles of children and young adults with solid tumors.

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Dominik Mumberg, PhD of Bayer @Bayer @BayerPharma discusses the investigational small molecule aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964 to be presented at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I. The AhR receptor is expressed in many different immune cells and is considered to play an important role in immuno-suppression within the tumor microenvironment. An AhR inhibitor such as BAY 2416964 is thought to reactivate anti-tumor immune responses in a manner distinct from currently approved checkpoint inhibitors, and thus may provide a new approach for cancer immunotherapy. BAY 2416964 is currently investigated in a…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy™ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

Loretta Itri, MD of Immunomedics @ImmunomedicsInc discusses the FDA grants accelerated approval for Immunomedics’ trodelvy in previously-treated metastatic triple-negative breast cancer. Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvyâ„¢ (sacituzumab govitecan-hziy) for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC and is also the first FDA-approved anti-Trop-2 ADC.1…

David Hong, MD of MD Anderson Cancer Center @MDAndersonNews discusses at this year’s virtual AACR the efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations.